Recent News for SRPT - Sarepta Therapeutics, Inc.

Date Title
Dec 24 Company News For Dec 24, 2019
Dec 24 10 Biotech M&A Targets Under The Scanner For 2020
Dec 23 A Perspective On Biopharma's Record M&A Run In 2019
Dec 23 Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B
Dec 23 Sarepta Unveils $1.15 Billion Gene Therapy Deal — And Stock Pops
Dec 23 Sarepta Signs Gene Therapy Agreement With Roche for $1.15B
Dec 23 SDRL, APA among premarket gainers
Dec 23 Sarepta Stock Is Soaring on $1 Billion Deal With Roche
Dec 23 Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 23, 2019: SRPT, ROK, CNSL, DPW, XFOR
Dec 23 Sarepta +13% premarket on SRP-9001 deal with Roche outside U.S.
Dec 23 Roche enters $1.15 billion licensing deal for Sarepta gene therapy
Dec 23 Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001
Dec 19 One particular field of drug development could dominate M&A in 2020
Dec 18 Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug
Dec 18 Solid Biosciences stock are up on DMD study news
Dec 17 8 Biotech Stocks Morgan Stanley Recommends For 2020
Dec 17 Sarepta Therapeutics: FDA Approval Reinstalls Confidence In The Pipeline
Dec 16 This Looks Like Just the Beginning for Sarepta Therapeutics (SRPT) Stock
Dec 16 Why This Biotech's 50% Plunge Will Ultimately Benefit Its Biggest Rival
Dec 16 Cambridge biotech's stock price tumbles on Duchenne drug failure
Dec 16 Wave craters 59% premarket on exit from DMD
Dec 14 Once Shunned For Marketing Approval, Golodirsen Is Now A Major Win For Sarepta
Dec 13 Mid-Day Market Update: Crude Oil Rises Over 1%; Sarepta Therapeutics Shares Spike Higher
Dec 13 SRPT, TRXC, ONCS and CEI among midday movers
Dec 13 Sarepta Rockets On Stunning Reversal For Previously Rejected Drug

Back to the Main SRPT Page...